GlassScriptPhysician profile
Thomas Pechin
NPI 1972951945
$4,920.41
in general payments reported to CMS, 2019-2025
38 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.51 · 2020: $255 · 2021: $785 · 2022: $514 · 2023: $838 · 2024: $1,397 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,271 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,271.12 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $775.71 | 2021-2025 | |
| Lilly USA, LLC | $453.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $382.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $358.68 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $312.10 | 2020-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.63 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $213.91 | 2019-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $193.16 | 2021-2025 | |
| Glaxosmithkline, LLC. | $165.47 | 2021-2024 | Trelegy Ellipta, Bexsero |
| Lundbeck LLC | $142.37 | 2023-2025 | Rexulti |
| Indivior INC. | $132.68 | 2023-2025 | Sublocade |
| Amgen INC. | $127.77 | 2022-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $113.69 | 2021-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $111.19 | 2019-2023 | |
| Mylan Specialty L.P. | $90.39 | 2024 | Yupelri |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $89.49 | 2024-2025 | Rexulti |
| Insulet Corporation | $85.68 | 2021-2025 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $85.40 | 2021-2025 | Trintellix, Gattex |
| Axsome Therapeutics, INC. | $79.83 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.00 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $73.78 | 2025 | Fanapt |
| Exact Sciences Corporation | $67.81 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $65.88 | 2021-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.77 | 2023-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $43.74 | 2021-2022 | |
| Viatris Specialty LLC | $43.48 | 2025 | Yupelri |
| Edwards Lifesciences Corporation | $38.49 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Phathom Pharmaceuticals, INC. | $38.18 | 2024 | Voquezna |
| Medtronic, INC. | $29.74 | 2023 | Intellis Adaptivestim |
| Eisai INC. | $29.70 | 2020 | |
| Biogen, INC. | $28.88 | 2021 | |
| Verona Pharma, INC. | $25.46 | 2025 | Ohtuvayre |
| Neurocrine Biosciences, INC. | $24.41 | 2025 | |
| Allergan, INC. | $23.49 | 2020 | |
| Alkermes, INC. | $19.85 | 2024 | Vivitrol |
| Sanofi Pasteur INC. | $19.01 | 2022 | |
| Gilead Sciences, INC. | $17.28 | 2025 | |
| Braintree Laboratories, INC. | $13.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pechin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.